$350 | Single User
$700 | Site License
$1050 | Enterprise License

Pharmaceuticals in Asia-Pacific [Report Updated: 30-06-2017]

Published by Marketline: 30 Jun 2017 | 100141 | In Stock

Introduction

Pharmaceuticals in Asia-Pacific

Summary

Pharmaceuticals in Asia-Pacific industry profile provides top-line qualitative and quantitative summary information including: market share, market size (value 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Synopsis

Essential resource for top-line data and analysis covering the Asia-Pacific pharmaceuticals market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

Key Highlights

- The pharmaceuticals market consists of ethical drugs only and does not include consumer healthcare or animal healthcare. Market values have been calculated at ex-factory prices (the value at which manufacturers sell the drugs to distributors). Any currency conversions used in the production of this report have been calculated at constant 2016 annual average exchange rates.

- The Asia-Pacific pharmaceuticals market had total revenues of 6.4bn in 2016, representing a compound annual growth rate (CAGR) of 6.4% between 2012 and 2016.

- The regional market is dominated by the Chinese, which is also proving to be a major growth area due to rising incomes and a greater emphasis placed on healthcare. However, the Chinese market is quite fragmented, making it more attractive to foreign and domestic companies to consolidate through merger and acquisition.

- Although certain markets such as China, India and Indonesia are growing at a fast pace, more mature markets such as South Korea and Japan are not. Governments are keen to keep costs down as the healthcare demands from an aging population grow. Greater emphasis is being placed on generic drugs and pharmaceutical companies are under public pressure to provide cost effective drugs.

Scope

- Save time carrying out entry-level research by identifying the size, growth, and leading players in the pharmaceuticals market in Asia-Pacific

- Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the pharmaceuticals market in Asia-Pacific

- Leading company profiles reveal details of key pharmaceuticals market players’ global operations and financial performance

- Add weight to presentations and pitches by understanding the future growth prospects of the Asia-Pacific pharmaceuticals market with five year forecasts

Reasons to buy

- What was the size of the Asia-Pacific pharmaceuticals market by value in 2016?

- What will be the size of the Asia-Pacific pharmaceuticals market in 2021?

- What factors are affecting the strength of competition in the Asia-Pacific pharmaceuticals market?

- How has the market performed over the last five years?

- Who are the top competitiors in Asia-Pacific's pharmaceuticals market?

Table of Contents
for Pharmaceuticals in Asia-Pacific [Report Updated: 30-06-2017]

  • Table of Contents

    Executive Summary

    Market value

    Market value forecast

    Geography segmentation

    Market share

    Market rivalry

    Market Overview

    Market definition

    Market analysis

    Market Data

    Market value

    Market Segmentation

    Geography segmentation

    Market share

    Market Outlook

    Market value forecast

    Five Forces Analysis

    Summary

    Buyer power

    Supplier power

    New entrants

    Threat of substitutes

    Degree of rivalry

    Leading Companies

    Daiichi Sankyo Co., Ltd.

    Shanghai Pharmaceuticals Holding Co Ltd

    Takeda Pharmaceutical Company Limited

    Yangtze River Pharmaceutical Group

    Methodology

    Industry associations

    Related MarketLine research

    Appendix

    About MarketLine

List Of Tables
in Pharmaceuticals in Asia-Pacific [Report Updated: 30-06-2017]

List of Tables

Table 1: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16

Table 2: Asia–Pacific pharmaceuticals market geography segmentation: $ billion, 2016

Table 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2016

Table 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21

Table 5: Daiichi Sankyo Co., Ltd.: key facts

Table 6: Daiichi Sankyo Co., Ltd.: key financials ($)

Table 7: Daiichi Sankyo Co., Ltd.: key financials (¥)

Table 8: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 9: Shanghai Pharmaceuticals Holding Co Ltd: key facts

Table 10: Shanghai Pharmaceuticals Holding Co Ltd: key financials ($)

Table 11: Shanghai Pharmaceuticals Holding Co Ltd: key financials (CNY)

Table 12: Shanghai Pharmaceuticals Holding Co Ltd: key financial ratios

Table 13: Takeda Pharmaceutical Company Limited: key facts

Table 14: Takeda Pharmaceutical Company Limited: key financials ($)

Table 15: Takeda Pharmaceutical Company Limited: key financials (¥)

Table 16: Takeda Pharmaceutical Company Limited: key financial ratios

Table 17: Yangtze River Pharmaceutical Group: key facts

List Of Figures, Charts and Diagrams
in Pharmaceuticals in Asia-Pacific [Report Updated: 30-06-2017]

List of Figures

Figure 1: Asia-Pacific pharmaceuticals market value: $ billion, 2012–16

Figure 2: Asia–Pacific pharmaceuticals market geography segmentation: % share, by value, 2016

Figure 3: Asia-Pacific pharmaceuticals market share: % share, by value, 2016

Figure 4: Asia-Pacific pharmaceuticals market value forecast: $ billion, 2016–21

Figure 5: Forces driving competition in the pharmaceuticals market in Asia-Pacific, 2016

Figure 6: Drivers of buyer power in the pharmaceuticals market in Asia-Pacific, 2016

Figure 7: Drivers of supplier power in the pharmaceuticals market in Asia-Pacific, 2016

Figure 8: Factors influencing the likelihood of new entrants in the pharmaceuticals market in Asia-Pacific, 2016

Figure 9: Factors influencing the threat of substitutes in the pharmaceuticals market in Asia-Pacific, 2016

Figure 10: Drivers of degree of rivalry in the pharmaceuticals market in Asia-Pacific, 2016

Figure 11: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 12: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 13: Shanghai Pharmaceuticals Holding Co Ltd: revenues & profitability

Figure 14: Shanghai Pharmaceuticals Holding Co Ltd: assets & liabilities

Figure 15: Takeda Pharmaceutical Company Limited: revenues & profitability

Figure 16: Takeda Pharmaceutical Company Limited: assets & liabilities

Additional Details

Publisher

Marketline

Publisher Information

Reference

100141 |

Number of Pages

35

Report Format

PDF

Marketline Reports

Related Reports

TitleDate PublishedPrice fromMore Details
Alexion Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Alnylam Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
AMAG Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Amylin Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
BioCryst Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Biomarin Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Enzon Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Essilor Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
Isis Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info
NPS Pharmaceuticals Partnering Deals and Alliances 2010 to 2016
The Partnering Deals and Alliance since 2010 report provides an in-depth insight into the partnering...
01 Oct 2016 by Current Partnering USD $1,495 More Info

This report is published by Marketline

Download Free Report Summary PDF

Pharmaceuticals in Asia-Pacific [Report Updated: 30-06-2017] | Download PDF Summary

Download our FREE report summary PDF. It contains all the information on these web pages, plus a Proforma Invoice request form, should you need it to satisfy your company's internal order procedures.

Ordering Information

Orders are processed immediately and you will be notified of the despatch date on confirmation of your order.

Accepted Card Types

Payment

Buy now using our secure payment system.

We Stock...

  • Allied Market Research
  • CBR Pharma
  • Current Partnering
  • Firstword
  • Global Data
  • Global Markets Direct
  • ICD Research
  • Infinti Research Technavio
  • Marketline
  • Markets and Markets
  • Micro Markets Monitor
  • MP Advisors
  • Venture Planning Group
  • GMR Data